Autophagy induction in the treatment of Alzheimer's disease
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
A growing body of evidence indicates that autophagy, an intracellular degradation pathway, profoundly affects Alzheimer's disease (AD) pathogenesis. Autophagy mediates the degradation of neurotoxic material and damaged organelles, allowing their clearance by glial and neuronal cells, while impaired autophagy may account for the accumulation of protein aggregates. Accordingly, dysfunctional autophagy is one of AD hallmarks; it occurs early in the disease development, which makes it an attractive therapeutic intervention target. Therefore, in recent years, the potential of autophagy induction as a treatment for AD has been studied extensively using various autophagy inducers, most of which are already in clinical practice for other medical conditions. Albeit promising results, including in AD clinical trials, this therapeutic strategy still requires careful consideration in order to fully understand the role of autophagy in AD pathogenesis and to further improve the outcomes. This review summarizes the current findings in this field and raises open questions and new prospects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
Leeman, D. S., Hebestreit, K., Ruetz, T., Webb, A. E., McKay, A., Pollina, E. A., Dulken, B. W., Zhao, X., Yeo, R. W., Ho, T. T., et al. (2018) · Science · doi:10.1126/science.aag3048 · Cited by 528 · cited 1×
“…(e.g., the approved drug digoxin and a curcumin derivative) as well as TFEB overexpression were shown to enhance autophagic/lysosomal activity in neuronal and glial cells in vitro and in vivo (Kilpatrick, Zeng, Hancock, & Segatori, 2015; Leeman et al., 2018; Song et al., 2016; Wang et al., 2017).”
BackgroundNeuroprotective Mechanisms of Resveratrol in Alzheimer’s Disease: Role of SIRT1
Gomes, B. A. Q., Silva, J. P. B., Romeiro, C. F. R., dos Santos, S. M., Rodrigues, C. A., Gonçalves, P. R., Sakai, J. T., Mendes, P. F. S., Varela, E. L. P., & Monteiro, M. C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8152373 · Cited by 403 · cited 1×
“Another activator of autophagy, also acting through the AMPK/mTORC1 pathway, is resveratrol, which was reported to reduce Aβ toxicity and to improve cognitive function mainly in AD animal models (Gomes et al., 2018).”
BackgroundAutophagy mediates pharmacological lifespan extension by spermidineand resveratrol
Morselli, E., Galluzzi, L., Kepp, O., Criollo, A., Maiuri, M. C., Tavernarakis, N., Madeo, F., & Kroemer, G. (2009) · Aging · doi:10.18632/aging.100110 · Cited by 213
Spermidine: A physiological autophagy inducer acting as an anti-aging vitamin in humans?
Madeo, F., Bauer, M. A., Carmona-Gutierrez, D., & Kroemer, G. (2019) · Autophagy · doi:10.1080/15548627.2018.1530929 · Cited by 212
Adverse events associated with mTOR inhibitors
Pallet, N., & Legendre, C. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752814 · Cited by 198
Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
Geifman, N., Brinton, R. D., Kennedy, R. E., Schneider, L. S., & Butte, A. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0237-y · Cited by 191
Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review
Canhada, S., Castro, K., Perry, I. S., & Luft, V. C. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1321813 · Cited by 156
Impaired Autophagy in APOE4 Astrocytes
Simonovitch, S., Schmukler, E., Bespalko, A., Iram, T., Frenkel, D., Holtzman, D. M., Masliah, E., Michaelson, D. M., & Pinkas-Kramarski, R. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-151101 · Cited by 136
Self-citationCholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion
Barbero-Camps, E., Roca-Agujetas, V., Bartolessis, I., de Dios, C., Fernández-Checa, J. C., Marí, M., Morales, A., Hartmann, T., & Colell, A. (2018) · Autophagy · doi:10.1080/15548627.2018.1438807 · Cited by 125
Cited by
mTOR signaling and Alzheimer's disease: What we know and where we are?
Davoody, S., Asgari Taei, A., Khodabakhsh, P., & Dargahi, L. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14463 · Cited by 96
Suelves, N., Saleki, S., Ibrahim, T., Palomares, D., Moonen, S., Koper, M. J., Vrancx, C., Vadukul, D. M., Papadopoulos, N., Viceconte, N., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01578-x · Cited by 43
“In this regard, it is important to note that autophagy-inducing agents such as rapamycin have been used in preclinical and clinical trials for the treatment of AD with promising outcomes [104].”
BackgroundAdvancements in autophagy perturbations in Alzheimer’s disease: Molecular aspects and therapeutics
Dhapola, R., Kumari, S., Sharma, P., Vellingiri, B., & HariKrishnaReddy, D. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149494 · Cited by 17
Wang, Y., Xiao, Z., Yin, H., Ren, Z., Ma, X., Wang, Y., Zhang, Y., Fu, X., Zhang, F., & Zeng, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37589 · Cited by 5
Metadata
- Authors
- Schmukler, E., & Pinkas‐Kramarski, R.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 2019-11-29
- Volume
- 81
- Issue
- 2
- Pages
- 184-193
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2990987222
- Cited by
- 43
- References
- 10
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autophagy induction in the treatment of Alzheimer's disease. https://app.cochat.ai/papers/10.1002/ddr.21605
- The paper
- Schmukler, E., & Pinkas‐Kramarski, R. (2020). Autophagy induction in the treatment of Alzheimer's disease. Drug Development Research. https://doi.org/10.1002/ddr.21605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.